Pemazyre (pemigatinib)

pCPA File Number: 22533

Negotiation Status:

Active Negotiation

Indication(s):

Unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement and a ECOG performance status of 0 to 2, Previously treated, in adults

Sponsor/Manufacturer:

Incyte Biosciences Canada Corporation

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2024-03-07

Negotiation Process Concluded:

Not Applicable